Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
GlobeNewswire
· Fifth Data and Safety Monitoring Board (DSMB) meeting recommended the continuation, without modifications, of the Phase 2b/3..